AAIITO Expert Consensus Reframes Mild-to-Moderate Asthma Toward Proactive Control
An Italian Delphi and RAND/UCLA consensus pushes pharmacists toward proactive, phenotype-informed, ICS-containing regimens rather than symptom-driven reliever use in mild-to-moderate asthma.
📅 Journal publication: Oct 2026(online Aug 6, 2026)·Last updated: Aug 7, 2026
Expert consensus on Management of Mild and Moderate AsthmaAAIITOmild-to-moderate asthmainhaled corticosteroidsICS/LABAbiomarkersFeNOeosinophilsPulmonology / Respiratory
Background Information
Expert consensus offers new guidelines for mild-to-moderate asthma management.
Mild and moderate asthma often remain poorly controlled, leading to exacerbations and limitations in daily activities. Consensus on asthma management includes optimal control without symptoms and exacerbations, using personalized treatment and patient education. These consensus guidelines provide practical recommendations validated for clinical appropriateness to improve asthma management and control. A proactive, patient-centric approach is key to managing mild-to-moderate asthma effectively.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Martini M, Cecchi L, Musarra A, Jaubashi K, Marra AM, Murzilli F, Papia F, Valenti G, Yang B, Cazzola M, Vaghi A, Bilò MB
Citation:Martini M, Cecchi L, Musarra A, et al. Expert consensus on the management of mild and moderate asthma. Respiratory medicine. 2026;262:109078. doi:10.1016/j.rmed.2026.109078